| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.087 | 0.06 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.06 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.06 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.06 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |